MovDisordV3, Main, Exploration, bibRecord, 000181

Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease.

Identifieur interne : 000181 ( Main/Exploration ); précédent : 000180; suivant : 000182

Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease.

Auteurs : Karen E. Murphy [Australie] ; Amanda M. Gysbers [Australie] ; Sarah K. Abbott [Australie] ; Adena S. Spiro [Australie] ; Akiko Furuta [Japon] ; Antony Cooper [Australie] ; Brett Garner [Australie] ; Tomohiro Kabuta [Japon] ; Glenda M. Halliday [Australie]

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.

RBID : pubmed:25594542

Abstract

Lysosomes are the primary catabolic compartment for the degradation of intracellular proteins through autophagy. The presence of abnormal intracellular α-synuclein-positive aggregates in Parkinson's disease (PD) indicates that the degradative capacity of lysosomes is impaired in PD. Specific dysfunction of chaperone-mediated autophagy (CMA) in PD is suggested by reductions in the CMA membrane receptor, lysosomal-associated membrane protein (LAMP) 2A, although whether LAMP2A is the only LAMP2 isoform affected by PD is unknown. Messenger RNA (mRNA) and protein expression of all three LAMP2 isoforms was assessed in brain extracts from regions with and without PD-related increases in α-synuclein in autopsy samples from subjects in the early pathological stage of PD (n = 9), compared to age- and postmortem delay-matched controls (n = 10). In the early stages of PD, mRNA expression of all LAMP2 isoforms was not different from controls, with LAMP2B and LAMP2C protein levels also unchanged in PD. The selective loss of LAMP2A protein directly correlated with the increased levels of α-synuclein and decreased levels of the CMA chaperone heat shock cognate protein 70 in the same PD samples, as well as with the accumulation of cytosolic CMA substrate proteins. Our data show that LAMP2 protein isoforms are differentially affected in the early stages of PD, with LAMP2A selectively reduced in association with increased α-synuclein, and suggests that dysregulation of CMA-mediated protein degradation occurs before substantial α-synuclein aggregation in PD. © 2015 International Parkinson and Movement Disorder Society.

DOI: 10.1002/mds.26141
PubMed: 25594542

Affiliations:

Australie, Japon
Sydney, Tokyo

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease.</title>
<author><name sortKey="Murphy, Karen E" sort="Murphy, Karen E" uniqKey="Murphy K" first="Karen E" last="Murphy">Karen E. Murphy</name>
<affiliation wicri:level="3"><nlm:affiliation>Neuroscience Research Australia, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Neuroscience Research Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gysbers, Amanda M" sort="Gysbers, Amanda M" uniqKey="Gysbers A" first="Amanda M" last="Gysbers">Amanda M. Gysbers</name>
<affiliation wicri:level="3"><nlm:affiliation>Neuroscience Research Australia, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Neuroscience Research Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Abbott, Sarah K" sort="Abbott, Sarah K" uniqKey="Abbott S" first="Sarah K" last="Abbott">Sarah K. Abbott</name>
<affiliation wicri:level="1"><nlm:affiliation>Illawarra Health and Medical Research Institute, Wollongong, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Illawarra Health and Medical Research Institute, Wollongong</wicri:regionArea>
<wicri:noRegion>Wollongong</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Spiro, Adena S" sort="Spiro, Adena S" uniqKey="Spiro A" first="Adena S" last="Spiro">Adena S. Spiro</name>
<affiliation wicri:level="1"><nlm:affiliation>Illawarra Health and Medical Research Institute, Wollongong, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Illawarra Health and Medical Research Institute, Wollongong</wicri:regionArea>
<wicri:noRegion>Wollongong</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Furuta, Akiko" sort="Furuta, Akiko" uniqKey="Furuta A" first="Akiko" last="Furuta">Akiko Furuta</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cooper, Antony" sort="Cooper, Antony" uniqKey="Cooper A" first="Antony" last="Cooper">Antony Cooper</name>
<affiliation wicri:level="3"><nlm:affiliation>The Garvan Institute of Medical Research, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Garvan Institute of Medical Research, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garner, Brett" sort="Garner, Brett" uniqKey="Garner B" first="Brett" last="Garner">Brett Garner</name>
<affiliation wicri:level="1"><nlm:affiliation>Illawarra Health and Medical Research Institute, Wollongong, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Illawarra Health and Medical Research Institute, Wollongong</wicri:regionArea>
<wicri:noRegion>Wollongong</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kabuta, Tomohiro" sort="Kabuta, Tomohiro" uniqKey="Kabuta T" first="Tomohiro" last="Kabuta">Tomohiro Kabuta</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M" last="Halliday">Glenda M. Halliday</name>
<affiliation wicri:level="3"><nlm:affiliation>Neuroscience Research Australia, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Neuroscience Research Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25594542</idno>
<idno type="pmid">25594542</idno>
<idno type="doi">10.1002/mds.26141</idno>
<idno type="wicri:Area/PubMed/Corpus">000290</idno>
<idno type="wicri:Area/PubMed/Curation">000290</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000181</idno>
<idno type="wicri:Area/Ncbi/Merge">004219</idno>
<idno type="wicri:Area/Ncbi/Curation">004219</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004219</idno>
<idno type="wicri:Area/Main/Merge">000181</idno>
<idno type="wicri:Area/Main/Curation">000181</idno>
<idno type="wicri:Area/Main/Exploration">000181</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease.</title>
<author><name sortKey="Murphy, Karen E" sort="Murphy, Karen E" uniqKey="Murphy K" first="Karen E" last="Murphy">Karen E. Murphy</name>
<affiliation wicri:level="3"><nlm:affiliation>Neuroscience Research Australia, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Neuroscience Research Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gysbers, Amanda M" sort="Gysbers, Amanda M" uniqKey="Gysbers A" first="Amanda M" last="Gysbers">Amanda M. Gysbers</name>
<affiliation wicri:level="3"><nlm:affiliation>Neuroscience Research Australia, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Neuroscience Research Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Abbott, Sarah K" sort="Abbott, Sarah K" uniqKey="Abbott S" first="Sarah K" last="Abbott">Sarah K. Abbott</name>
<affiliation wicri:level="1"><nlm:affiliation>Illawarra Health and Medical Research Institute, Wollongong, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Illawarra Health and Medical Research Institute, Wollongong</wicri:regionArea>
<wicri:noRegion>Wollongong</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Spiro, Adena S" sort="Spiro, Adena S" uniqKey="Spiro A" first="Adena S" last="Spiro">Adena S. Spiro</name>
<affiliation wicri:level="1"><nlm:affiliation>Illawarra Health and Medical Research Institute, Wollongong, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Illawarra Health and Medical Research Institute, Wollongong</wicri:regionArea>
<wicri:noRegion>Wollongong</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Furuta, Akiko" sort="Furuta, Akiko" uniqKey="Furuta A" first="Akiko" last="Furuta">Akiko Furuta</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cooper, Antony" sort="Cooper, Antony" uniqKey="Cooper A" first="Antony" last="Cooper">Antony Cooper</name>
<affiliation wicri:level="3"><nlm:affiliation>The Garvan Institute of Medical Research, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The Garvan Institute of Medical Research, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garner, Brett" sort="Garner, Brett" uniqKey="Garner B" first="Brett" last="Garner">Brett Garner</name>
<affiliation wicri:level="1"><nlm:affiliation>Illawarra Health and Medical Research Institute, Wollongong, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Illawarra Health and Medical Research Institute, Wollongong</wicri:regionArea>
<wicri:noRegion>Wollongong</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kabuta, Tomohiro" sort="Kabuta, Tomohiro" uniqKey="Kabuta T" first="Tomohiro" last="Kabuta">Tomohiro Kabuta</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M" last="Halliday">Glenda M. Halliday</name>
<affiliation wicri:level="3"><nlm:affiliation>Neuroscience Research Australia, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Neuroscience Research Australia, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lysosomes are the primary catabolic compartment for the degradation of intracellular proteins through autophagy. The presence of abnormal intracellular α-synuclein-positive aggregates in Parkinson's disease (PD) indicates that the degradative capacity of lysosomes is impaired in PD. Specific dysfunction of chaperone-mediated autophagy (CMA) in PD is suggested by reductions in the CMA membrane receptor, lysosomal-associated membrane protein (LAMP) 2A, although whether LAMP2A is the only LAMP2 isoform affected by PD is unknown. Messenger RNA (mRNA) and protein expression of all three LAMP2 isoforms was assessed in brain extracts from regions with and without PD-related increases in α-synuclein in autopsy samples from subjects in the early pathological stage of PD (n = 9), compared to age- and postmortem delay-matched controls (n = 10). In the early stages of PD, mRNA expression of all LAMP2 isoforms was not different from controls, with LAMP2B and LAMP2C protein levels also unchanged in PD. The selective loss of LAMP2A protein directly correlated with the increased levels of α-synuclein and decreased levels of the CMA chaperone heat shock cognate protein 70 in the same PD samples, as well as with the accumulation of cytosolic CMA substrate proteins. Our data show that LAMP2 protein isoforms are differentially affected in the early stages of PD, with LAMP2A selectively reduced in association with increased α-synuclein, and suggests that dysregulation of CMA-mediated protein degradation occurs before substantial α-synuclein aggregation in PD. © 2015 International Parkinson and Movement Disorder Society.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Japon</li>
</country>
<settlement><li>Sydney</li>
<li>Tokyo</li>
</settlement>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Murphy, Karen E" sort="Murphy, Karen E" uniqKey="Murphy K" first="Karen E" last="Murphy">Karen E. Murphy</name>
</noRegion>
<name sortKey="Abbott, Sarah K" sort="Abbott, Sarah K" uniqKey="Abbott S" first="Sarah K" last="Abbott">Sarah K. Abbott</name>
<name sortKey="Cooper, Antony" sort="Cooper, Antony" uniqKey="Cooper A" first="Antony" last="Cooper">Antony Cooper</name>
<name sortKey="Garner, Brett" sort="Garner, Brett" uniqKey="Garner B" first="Brett" last="Garner">Brett Garner</name>
<name sortKey="Gysbers, Amanda M" sort="Gysbers, Amanda M" uniqKey="Gysbers A" first="Amanda M" last="Gysbers">Amanda M. Gysbers</name>
<name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M" last="Halliday">Glenda M. Halliday</name>
<name sortKey="Spiro, Adena S" sort="Spiro, Adena S" uniqKey="Spiro A" first="Adena S" last="Spiro">Adena S. Spiro</name>
</country>
<country name="Japon"><noRegion><name sortKey="Furuta, Akiko" sort="Furuta, Akiko" uniqKey="Furuta A" first="Akiko" last="Furuta">Akiko Furuta</name>
</noRegion>
<name sortKey="Kabuta, Tomohiro" sort="Kabuta, Tomohiro" uniqKey="Kabuta T" first="Tomohiro" last="Kabuta">Tomohiro Kabuta</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000181 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000181 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25594542
   |texte=   Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25594542" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease.

Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.